SightfileU.S. market data from official filings

XERIS BIOPHARMA HOLDINGS INC (XERS)

Name: XERIS BIOPHARMA HOLDINGS INC (XERS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001867096 · EDGAR filings · Updated 2026-07-17

XERIS BIOPHARMA HOLDINGS INC (XERS) has reported institutional ownership of 60.9%, with 236 institutional managers holding positions valued at $611.1M per the latest 13F reporting period.

Institutional ownership

60.9%

Institutional managers

236

Reported 13F value

$611.1M

Insider activity

55 trans.

−$3.59M net selling

Latest updates

2026-07-17 — Current report (8-K) filed
2026-07-07 — Insider transaction reported (Form 4)
2026-07-07 — Notice of proposed sale filed (Form 144)
2026-07-06 — Notice of proposed sale filed (Form 144)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Initial insider ownership filed (Form 3)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, XERIS BIOPHARMA HOLDINGS INC has 236 institutional holders and institutional ownership of 60.9%.

Insider activity

Insiders reported 55 transactions (1 buys, 15 sells) across 11 reporting insiders, with a net reported value of −$3.59M.

Related companies

AKTIS ONCOLOGY INC (AKTS) · REPLIMUNE GROUP INC (REPL) · STEVANATO GROUP S P A (STVN) · OMADA HEALTH INC (OMDA) · BIOAGE LABS INC (BIOA) · MEIRAGTX HLDGS PLC (MGTX)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-17.